Clinical studies of MOLOGEN AG

Currently, the MOLOGEN main product Lefitolimod is being tested in four clinical trials: IMPALA (indication colorectal cancer), IMPULSE (indication small-cell lung cancer), TEACH (indication HIV), and a combination study with the immunotherapy Yervoy® (Impilimumab) in patients with advanced tumors.

IMPALA Study
IMPULSE Study
TEACH Study
Combination study with Yervoy®

We specifically point out that the information on this website is in no way intended to replace the advice of a doctor or to be understood as a medical recommendation.

As a patient, you should always seek comprehensive medical advice before making any decisions regarding your treatment.